Cardiovascular risk management by blocking the endocannabinoid system
UNSPECIFIED. (2006) Cardiovascular risk management by blocking the endocannabinoid system. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 114 (2). pp. 75-81. ISSN 0947-7349Full text not available from this repository.
Official URL: http://dx.doi.org/10.1055/s-2006-923885
The specific blockade of endocannabinoids at the level of the cannabinoid receptor 1 (CB1 receptor) is a new therapeutic option to reduce body weight and manage cardiovascular risk. Although clinical trials are underway to document the safety and efficacy of this approach, Much is Still unknown about this endogenous system. Endocannabinoids and their receptors are expressed in the central nervous system as well as in the periphery and regulate the central neural circuits for food uptake and peripheral metabolic circuits. Within the context of food uptake, the stimulation of the CB, receptor with Delta(9)-tetrahydrocannabiol (Delta(9)-THC) enhances food consumption, while its blockade with receptor antagonists is an emerging relevant therapeutic means to reduce body weight. Rimonabant is the first of a new class of drugs that interferes with the endocannabinoid system by blocking the CB1 receptor. In recent clinical studies, a substantial reduction in body weight and waist circumference was associated with an improvement of the cardiovascular risk profile. In particular, increased HDL cholesterol, decreased serum triglycerides and improved insulin sensivity were observed. Further research will serve to establish the role of these compounds in cardiovascular risk management.
|Item Type:||Journal Article|
|Subjects:||R Medicine > RC Internal medicine|
|Journal or Publication Title:||EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES|
|Publisher:||JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH|
|Official Date:||February 2006|
|Number of Pages:||7|
|Page Range:||pp. 75-81|
Actions (login required)
Downloads per month over past year